CORT
Corcept TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
CORT vs peer average
56/100
CORT vs. peer average (C vs. C)
Grade spread
A 1 · B 1 · C 4 · D 3 · F 2
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
LEGN is the first available peer comparator.
Legend Biotech is an imperfect but more relevant oncology-commercial peer because investors value it on the durability of a marketed oncology asset plus pipeline optionality; compared with LEGN, Corcept is earlier in building oncology revenue but now has an approved ovarian-cancer product and follow-on studies.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
CORT
Corcept Therapeutics
LEGN
Legend Biotech
Grade
C
F
Momentum
98
6
Value
58
41
Sentiment
1
63
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Defensive
Grade position vs LEGN
CORT / LEGN
Grade Position
In line
CORT vs. peer average (C vs. C)
56/100
Momentum
98
CORTValue
58
CORTSentiment
1
LEGNRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs CORT
LEGN is the first peer returned for this comparison set.